Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RXO, Inc. Director's Dealing 2024

Aug 14, 2024

31516_dirs_2024-08-14_b864558d-dc11-408d-b298-6fee4fae6488.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXO, Inc. (RXO)
CIK: 0001929561
Period of Report: 2024-08-12

Reporting Person: MFN Partners, LP (N/A)
Reporting Person: MFN Partners GP, LLC (N/A)
Reporting Person: MFN Partners Management, LP (N/A)
Reporting Person: MFN Partners Management, LLC (N/A)
Reporting Person: DeMichele Michael (N/A)
Reporting Person: NANJI FARHAD (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-08-12 Common Stock P 10266810 $20.21 Acquired 27577666 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-08-12 Warrant to Purchase Common Stock $0.01 P 2558753 Acquired Common Stock (2558753) Direct

Footnotes

F1: MFN Partners, LP (the "Partnership") is the holder of the securities reported herein. MFN Partners GP, LLC ("MFN GP") is the general partner of the Partnership. MFN Partners Management, LP ("MFN Management") is the investment adviser to the Partnership. MFN Partners Management, LLC ("MFN LLC") is the general partner of MFN Management. Farhad Nanji and Michael F. DeMichele are managing members of MFN GP and MFN LLC. Each Reporting Person disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest, if any, therein.

F2: This Warrant can only be exercised to the extent that following such exercise the Partnership's beneficial ownership of the Issuer, together with any attribution parties, does not exceed 19.9%. The Warrant has no expiration date. This does not include an additional warrant for 2,018,574 shares of Common Stock with an exercise price of $0.01 and no expiration date, which becomes exercisable immediately upon the stockholders of the Issuer approving the issuance of the shares underlying that warrant pursuant to the applicable rules and regulations of the New York Stock Exchange. Upon such approval, that warrant can only be exercised to the extent that following such exercise the Partnership's beneficial ownership of the Issuer, together with any attribution parties, does not exceed 19.9%.